ORGANON & CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.37 USD | -0.15% |
|
+8.18% | +41.26% |
| May. 08 | Organon Reports Pricing of $1 Billion Senior Notes Offering | MT |
| May. 08 | Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 6.39B | Sales 2025 * | 6.47B | Capitalization | 5.24B |
|---|---|---|---|---|---|
| Net income 2024 * | 751M | Net income 2025 * | 971M | EV / Sales 2024 * | 2 x |
| Net Debt 2024 * | 7.56B | Net Debt 2025 * | 6.85B | EV / Sales 2025 * | 1.87 x |
| P/E ratio 2024 * |
7.02
x | P/E ratio 2025 * |
5.43
x | Employees | 10,000 |
| Yield 2024 * |
5.46% | Yield 2025 * |
5.67% | Free-Float | 99.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Organon & Co.
More recommendations
More news
| 1 day | -0.15% | ||
| 1 week | +8.18% | ||
| Current month | +9.46% | ||
| 1 month | +12.17% | ||
| 3 months | +24.89% | ||
| 6 months | +66.01% | ||
| Current year | +41.26% |
1 week
19.41
20.97
1 month
17.3320.97
Current year
13.6520.97
1 year
10.8424.08
3 years
10.8439.48
5 years
10.8439.48
10 years
10.8439.48
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Ali
CEO | Chief Executive Officer | 63 | 21-06-01 |
Matthew Walsh
DFI | Director of Finance/CFO | 57 | 21-06-01 |
| Chief Tech/Sci/R&D Officer | 54 | 23-09-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rochelle Lazarus
BRD | Director/Board Member | 76 | 21-06-01 |
Carrie Cox
CHM | Chairman | 66 | 21-06-01 |
Robert Essner
BRD | Director/Board Member | 76 | 21-06-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.92% | 0 M€ | +12.09% | - | |
| 1.71% | 0 M€ | +8.89% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 20.37 | -0.15% | 2,114,086 |
| 24-05-07 | 20.4 | -1.35% | 2,438,275 |
| 24-05-06 | 20.68 | +5.46% | 3,180,132 |
| 24-05-03 | 19.61 | +0.56% | 3,217,591 |
| 24-05-02 | 19.5 | +3.56% | 4,580,564 |
Delayed Quote Nyse, May 08, 2024 at 04:00 pm EDT
More quotes
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Companyâs Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Sector
Pharmaceuticals
Calendar
2024-06-04
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
20.37
USD
Average target price
22.5
USD
Spread / Average Target
+10.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.26% | 5.25B | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
- Stock Market
- Equities
- OGN Stock